BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Mar 14, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analylst Picks & Changes

Analylst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 3/11 cls
Cadence Pharmaceuticals Inc. (NASDAQ:CADX) Ladenburg Thalmann Juan Sanchez Upgrade Neutral (from sell) 1% $8.74
Sanchez raised his target to $8 from $6 due to faster than expected formulary acceptance of Ofirmev IV acetaminophen in the U.S. to treat pain and fever.
Human Genome Sciences Inc. (NASDAQ:HGSI) Barclays Capital Jim Birchenough Price...

Read the full 510 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >